WFA of San Diego LLC acquired a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,850 shares of the medical research company’s stock, valued at approximately $835,000.

A number of other institutional investors and hedge funds have also made changes to their positions in BIO. FMR LLC grew its holdings in Bio-Rad Laboratories by 12.7% in the first quarter. FMR LLC now owns 182,762 shares of the medical research company’s stock worth $55,867,000 after purchasing an additional 20,560 shares during the period. Public Employees Retirement Association of Colorado grew its holdings in Bio-Rad Laboratories by 9.3% in the first quarter. Public Employees Retirement Association of Colorado now owns 3,255 shares of the medical research company’s stock worth $1,141,000 after purchasing an additional 277 shares during the period. New York State Common Retirement Fund grew its holdings in Bio-Rad Laboratories by 5.6% in the first quarter. New York State Common Retirement Fund now owns 41,200 shares of the medical research company’s stock worth $14,443,000 after purchasing an additional 2,200 shares during the period. Rhumbline Advisers grew its holdings in Bio-Rad Laboratories by 8.7% in the first quarter. Rhumbline Advisers now owns 56,939 shares of the medical research company’s stock worth $19,961,000 after purchasing an additional 4,557 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Bio-Rad Laboratories by 0.5% in the first quarter. Bank of New York Mellon Corp now owns 248,355 shares of the medical research company’s stock worth $87,063,000 after purchasing an additional 1,284 shares during the period. Institutional investors and hedge funds own 65.23% of the company’s stock.

Shares of NYSE:BIO traded up $1.30 during trading on Wednesday, reaching $514.12. 8,535 shares of the stock traded hands, compared to its average volume of 185,594. The stock has a 50-day moving average of $510.62 and a two-hundred day moving average of $448.96. Bio-Rad Laboratories, Inc. has a 52-week low of $309.38 and a 52-week high of $540.06. The stock has a market cap of $15.22 billion, a P/E ratio of 7.99 and a beta of 1.04.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, July 30th. The medical research company reported $1.61 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.39. Bio-Rad Laboratories had a net margin of 84.89% and a return on equity of 3.66%. The company had revenue of $536.88 million for the quarter, compared to analysts’ expectations of $526.80 million. Analysts predict that Bio-Rad Laboratories, Inc. will post 7.9 earnings per share for the current year.

In related news, EVP Giovanni Magni sold 2,382 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $518.81, for a total value of $1,235,805.42. Following the sale, the executive vice president now owns 12,435 shares in the company, valued at $6,451,402.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 27.50% of the company’s stock.

A number of equities research analysts have weighed in on BIO shares. Wells Fargo & Company restated a “buy” rating and issued a $590.00 price objective on shares of Bio-Rad Laboratories in a report on Thursday, September 3rd. Jefferies Financial Group reiterated a “market perform” rating and set a $666.00 price target on shares of Bio-Rad Laboratories in a report on Thursday, September 3rd. Finally, Citigroup increased their price target on shares of Bio-Rad Laboratories from $525.00 to $625.00 and gave the company a “buy” rating in a report on Friday, July 31st. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Bio-Rad Laboratories presently has a consensus rating of “Buy” and an average price target of $577.75.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Recommended Story: Book Value Per Share – BVPS

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.